Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 26, Issue 8, Pages 1223-1230Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2007.11.8877
Keywords
-
Categories
Funding
- NCI NIH HHS [CA38926, CA04919, CA12213, CA12644, CA13612, CA37981, CA16385, CA20319, CA22433, CA35996, CA27057, CA28862, CA35431, CA35281, CA42777, CA45377, CA58686, CA45560, CA58723, CA67663, CA67575, CA46113, CA46282, CA46441, CA52654, CA58861, CA58882, CA86780, CA76447, CA58416, CA58658, CA35178, CA35192, CA35176, CA35128, CA35261, CA35262, CA35119, CA35090, CA32102] Funding Source: Medline
Ask authors/readers for more resources
Purpose The late cardiac effects of adjuvant anthracycline therapy in survivors of early-stage breast cancer have had limited study. Subclinical and clinical cardiac late effects may contribute to added comorbidity over time. Patients and Methods We recruited patients treated on Southwest Oncology Group (SWOG) protocol S8897 who had been randomly assigned to adjuvant chemotherapy with or without doxorubicin. Left ventricular ejection fraction (LVEF) was evaluated at 5 to 8 years and 10 to 13 years after treatment randomization. Cardiac risk factors and events were reported by clinicians annually between the two assessments. Results A total of 180 breast cancer survivors from a potential sample of 1,176 patients were entered, 163 patients at 5 to 8 years and 17 additional patients at 10 to 13 years, with 93 longitudinal assessments of LVEF. There was no significant difference in the proportion of women with an LVEF less than 50% at 5 to 8 (cyclophosphamide, doxorubicin, and fluorouracil [CAF] v cyclophosphamide, methotrexate, and fluorouracil [CMF]: 5% v 7%; P = .68) or 10 to 13 years (CAF v CMF: 3% v 0%; P = .16); however, in an exploratory analysis, the mean LVEF in the doxorubicin group was statistically significantly lower in the 5- to 8-year sample (64.8% v 61.4%; P = .01) but not in the 10- to 13-year sample. In the longitudinal analysis, there was no significant deterioration in LVEF. Conclusion Women enrolled onto an adjuvant chemotherapy treatment clinical trial for breast cancer were successfully recruited to participate in a research study of the late effects of treatment, although many SWOG institutions and potentially eligible patients chose not to participate. In this selected sample, with up to 13 years of follow-up, exposure to doxorubicin did not increase the likelihood of adverse cardiac effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available